IL289192B1 - Method for treating idiopathic pulmonary fibrosis - Google Patents

Method for treating idiopathic pulmonary fibrosis

Info

Publication number
IL289192B1
IL289192B1 IL289192A IL28919221A IL289192B1 IL 289192 B1 IL289192 B1 IL 289192B1 IL 289192 A IL289192 A IL 289192A IL 28919221 A IL28919221 A IL 28919221A IL 289192 B1 IL289192 B1 IL 289192B1
Authority
IL
Israel
Prior art keywords
days
compound
administration
pharmaceutically acceptable
stereoisomer
Prior art date
Application number
IL289192A
Other languages
English (en)
Hebrew (he)
Other versions
IL289192A (en
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of IL289192A publication Critical patent/IL289192A/en
Publication of IL289192B1 publication Critical patent/IL289192B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL289192A 2019-06-25 2020-06-24 Method for treating idiopathic pulmonary fibrosis IL289192B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (2)

Publication Number Publication Date
IL289192A IL289192A (en) 2022-02-01
IL289192B1 true IL289192B1 (en) 2026-05-01

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289192A IL289192B1 (en) 2019-06-25 2020-06-24 Method for treating idiopathic pulmonary fibrosis

Country Status (10)

Country Link
US (1) US12582653B2 (cg-RX-API-DMAC7.html)
EP (1) EP3992183B1 (cg-RX-API-DMAC7.html)
JP (1) JP7615061B2 (cg-RX-API-DMAC7.html)
CN (2) CN114026072A (cg-RX-API-DMAC7.html)
AU (1) AU2020305979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144113A1 (cg-RX-API-DMAC7.html)
IL (1) IL289192B1 (cg-RX-API-DMAC7.html)
TW (1) TWI804743B (cg-RX-API-DMAC7.html)
WO (1) WO2020259528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS
US20250074908A1 (en) * 2022-01-13 2025-03-06 Wuhan Createrna Science And Technology Co., Ltd. Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
TW202423441A (zh) * 2022-10-13 2024-06-16 大陸商北京泰德製藥股份有限公司 治療塵肺病的方法
WO2025017500A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations of rock2 inhibitors for cns disorders
AU2024292342A1 (en) 2023-07-17 2026-02-26 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションLycera Corporation Rho関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
TWI800498B (zh) * 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2020259528A1 (zh) 2020-12-30
JP7615061B2 (ja) 2025-01-16
EP3992183B1 (en) 2026-07-15
JP2022539329A (ja) 2022-09-08
US20220233538A1 (en) 2022-07-28
EP3992183A4 (en) 2023-06-21
US12582653B2 (en) 2026-03-24
IL289192A (en) 2022-02-01
CN114026072A (zh) 2022-02-08
KR20220029681A (ko) 2022-03-08
TWI804743B (zh) 2023-06-11
EP3992183A1 (en) 2022-05-04
AU2020305979A1 (en) 2022-02-17
TW202114679A (zh) 2021-04-16
BR112021026214A2 (pt) 2022-02-15
CN119868365A (zh) 2025-04-25
AU2020305979B2 (en) 2026-04-23
CA3144113A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
IL289192A (en) Method for treating idiopathic pulmonary fibrosis
IL282988A (en) Methods of treatment for cystic fibrosis
EP3768270A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF IDIOPATHIC PULMONAL FIBROSIS
EP3689086C0 (en) MULTI-BEAM RANDOM ACCESS PROCEDURE IN THE EXECUTION OF A TRANSFER
EP4007756C0 (en) KIF18A INHIBITORS
EP3963061A4 (en) NEW OMNI 50 CRISPR NUCLEASES
EP3938136C0 (de) Hairpin-schweissverfahren
IL285110A (en) Methods of treating multiple myeloma
DK4051688T3 (da) Cd73-hæmmere
EP4048745A4 (en) Composition and method for dielectric cmp
EP3953503C0 (en) ELECTROLYTIC POLISHING PROCESS
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
IL278814A (en) Methods and preparations for the treatment of pulmonary hypertension
EP4046129C0 (fr) Procédé de fabrication
FI20165695A7 (fi) Menetelmä ja järjestelmä viherlipeän laadun optimoimiseksi
IL286040A (en) Methods of treating al amyloidosis
IL291208A (en) Concrete element and method for its production
EP3950970A4 (en) Steel rod
EP3959294C0 (de) Verölungsverfahren
EP4018836C0 (en) COCOA ALKALINIZATION PROCESS
IL287130A (en) Methods of treating pruritus
DK3825470T3 (da) Fugnings metode
FI3952858T3 (fi) Menetelmä kasvainten hoitamiseksi
EP3976797A4 (en) ANTI-CRISPR INHIBITORS
IL286857A (en) Methods for the treatment of beta-thalassemia